Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of K562 cells treated with the FTO inhibitor FB23-2

ABSTRACT: RNA-seq of K562 cells treated with the FTO inhibitor FB23-2

PROVIDER: PRJEB52885 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR9735860_1.fastq.gz	Fastqsanger.gz
	ERR9735860_2.fastq.gz	Fastqsanger.gz
	ERR9735855_1.fastq.gz	Fastqsanger.gz
	ERR9735855_2.fastq.gz	Fastqsanger.gz
	ERR9735856_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

RNA-seq of K562 cells treated with the FTO inhibitor CS2 compared to DMSO treated cells

Project description:Increased FTO expression has been connected to resistance to tyrosine kinase inhibitors in CML. To explore the therapeutic potential of targeting FTO in CML, we tested the FTO catalytic inhibitor in the K562 CML cell line. The RNA-seq was performed to identify relevant regulated genes.

2023-12-31 | E-MTAB-12774 | biostudies-arrayexpress

RNA-seq of K562 cells treated with the FTO inhibitor FB23-2

Project description:FB23-2 inhibits proliferation of K562 cells. The RNA-seq was performed to identify relevant regulated genes.

2023-12-01 | E-MTAB-11751 | biostudies-arrayexpress

Analysis of m6A levels in K562 treted with the FTO inhibitor FB23-3 by m6A-mRNA&lncRNA Epitranscriptomic Microarray

Project description:FTO, an N6-methyladenosine demethylase, has emerged as a promising target for the treatment of specific acute myeloid leukemia (AML) subtypes. Here, we investigate the antiproliferative effects of the FTO inhibitor FB23-2 in leukemia. We demonstrate that FB23-2 potently inhibits proliferation across both AML and CML cell lines, irrespective of their responsiveness to FTO depletion. Interestingly, FB23-2 induces cell cycle arrest without a concurrent increase in m6A levels, suggesting an alternative mechanism of action.

2024-12-26 | GSE254577 | GEO

Sequencing of mRNA with N6-methyladenosine (m6A) modification in AML cells upon DMSO or FTO inhibitor treatment

Project description:To identify the potential mRNA targets of FTO inhibitor, we conducted m6A-seq with mRNA samples enriched from AML cells upon DMSO and FB23-2 (FTO inhibitor) treatment

2019-04-29 | GSE103496 | GEO

RNA-seq of K562 cells treated with the FTO inhibitor CS2 compared to DMSO treated cells

Project description:RNA-seq of K562 cells treated with the FTO inhibitor CS2 compared to DMSO treated cells

| PRJEB60741 | ENA

FTO inhibition attenuates obstruction-induced kidney fibrosis by downregulating ferroptosis activator ACSL4 and profibrotic factor TGFBI

Project description:Analysis by LC-MS/MS shotgun proteomics was performed on lysates from the following samples: 1) Control HK2 cells generated using control CRISPR/CAS9 system and scrambled guide RNA (sgRNAGCACTCACATCGCTACATCA) 2) HK2 cells with FTO knockout using CRISPR/Cas9 system and target 2 guide RNA (sgCCTACAAGTACCTGAACACC) 3) HK2 cells with FTO knockout using CRISPR/Cas9 system and target 3 guide RNA (sgCCAGGCTCTTTACGGTCCCC) 4) HK2 cells treated with vehicle control 5) HK2 cells treated with erastin 6) HK2 cells treated with FTO inhibitor FB23-2

2025-10-13 | PXD051362 | Pride

FB23-2 exerts therapeutic effects against T-ALL through the FTO/m6A/MYC axis.

Project description:T-cell acute lymphoblastic leukemia (T-ALL) is a pediatric hematological malignancy that presents significant challenges. RNA N6-methyladenosine (m6A) methylation is crucial in tumorigenesis, and the m6A demethylase FTO has emerging importance in cancers; however, its specific role in T-ALL pathogenesis remains incompletely understood. In vitro studies employed T-ALL cell lines treated with the FTO inhibitor FB23-2. Our findings indicate that FB23-2 may exert therapeutic effects against T-ALL primarily through the FTO/m6A/MYC axis.

2026-05-19 | GSE317759 | GEO

RNA seq with AML (NB4) cells upon FTO inhibition

Project description:To determine the potential targets of FTO and identify treatment significance of FTO inhibition in AML, we conducted transcriptome wide RNA seq with NB4 cells upon DMSO and FTO inhibitors (FB23 and FB23-2) treatment.

2019-04-29 | GSE103495 | GEO

Targeting FTO suppresses hepatocellular carcinoma by inhibiting ERBB3 and TUBB4A expression [RNA-seq]

Project description:Fat mass and obesity-associated protein (FTO) is an N6-methyladenosine (m6A) demethylase and plays a critical oncogenic role in various cancers. Here we show that FTO is an effective target in hepatocellular carcinoma (HCC). FTO is highly expressed in clinical patients of HCC and presents as a poor prognostic factor. Genetic depletion of FTO dramatically attenuated HCC progression in vivo. Pharmacological inhibition of FTO by FB23/FB23-2 remarkably suppressed the proliferation and migration of HCC cell lines in vitro, as well as inhibiting the HCC tumorigenicity in xeno-transplanted mice. Mechanistically, FB23-2 suppressed the expression of Erb-b2 receptor tyrosine kinase 3 (ERBB3) and human tubulin beta class Iva (TUBB4A) by increasing the m6A level in these mRNA transcripts. The decreased ERBB3 resulted in inhibited Akt-mTOR signaling that subsequently impaired the proliferation and survival of HCC cells. Moreover, FB23-2 abolished the organization of the tubulin cytoskeleton, while enforced expression of TUBB4A rescued the migration of HCC cells. Collectively, our study demonstrated that FTO plays a critical role in HCC by maintaining the proliferation and migration of cells, and highlights the broad potential of FTO inhibitors for targeting HCC.

2025-01-03 | GSE268326 | GEO

Analysis of m6A levels in K562 treted with the FTO inhibitor FB23-3 by m6A-mRNA&lncRNA Epitranscriptomic Microarray

Project description:Analysis of m6A levels in K562 treted with the FTO inhibitor FB23-3 by m6A-mRNA&lncRNA Epitranscriptomic Microarray

| PRJNA1071078 | ENA